UPDATE: Sarepta Therapeutics (SRPT) Posts Wider-than-Expected Q2 Loss

Sarepta Therapeutics (NASDAQ: SRPT) reported Q2 EPS of ($1.35), versus the analyst estimate of ($1.23).

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• Oppenheimer turns cautious on major U.S. banks, favors alternative asset managers
• FB Financial Corporation Announces 2026 Second Quarter Earnings Call
• SportsMed Physical Therapy Named a 2026 Health Care Heroes Honoree